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Increased copy numbers of 17q23 chromosomal region have been shown to occur in different tumour types and to be associated
with tumour progression and with poor prognosis. Several genes have earlier been proposed as potential oncogenes at this region
largely on the grounds of cell lines studies. In this study, we performed a systematic gene expression survey on 26 primary breast
tumours with known 17q23 amplification status by quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR).
The 17q23 amplicon is restricted to an B5MB region in breast cancer and contains 29 known genes. Our survey revealed a
statistically significant (Po0.01) difference between the high level and no amplification groups in a set of eleven genes whereas no
difference between the moderate and the non-amplified tumour groups were observed. Interestingly, these 11 genes were located
adjacent to one another within a 1.56Mb core region in which all except one of the genes were overexpressed. These data suggest
that only high-level amplification at the 17q23 amplicon core leads to elevated gene expression in breast cancer. Moreover, our
results highlight the fact that 17q23 amplicon carries multiple candidate genes and that this may be a more common event in gene
amplification than previously thought.
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Gene amplification is one of the major mechanisms that allow
cancer cells to promote expression of genes that are involved in
tumour development and progression. Oncogene overexpression
as a result of gene amplification has been shown to play a crucial
part in the pathogenesis of various human malignancies, especially
in solid tumours such as breast, prostate, lung, ovarian, gastric,
pancreatic, and colon cancers (Knuutila et al, 1998). The first
illustration on the clinical significance of amplified oncogenes in
human cancer was the discovery of an association between
amplification of the MYC oncogene and more aggressive
neuroblastoma variants (Schwab, 1993). To date, one of the
clinically most important amplified gene is the ERBB2 oncogene,
which is well known for its central role as a prognostic and
predictive factor in breast cancer as well as a therapeutic target
(Baselga et al, 1999; Cobleigh et al, 1999; Ross and Fletcher, 1999;
Vogel et al, 2002). These examples illustrate that genes that are
altered by amplification in cancer are likely to have an impact on
both disease pathogenesis and the clinical management of cancer
patients.
Amplification of the chromosomal region 17q23 was first
discovered in breast cancer (Kallioniemi et al, 1994). After that,
numerous studies have reported increased copy numbers of 17q23
in tumours of brain, lung, ovary, pancreas, bladder, testis, and liver
(Muleris et al, 1994; Ried et al, 1994; Korn et al, 1996; Solinas-
Toldo et al, 1996; Brinkschmidt et al, 1997; Marchio et al, 1997;
Richter et al, 1997; Schwendel et al, 1997; Sonoda et al, 1997;
Weber et al, 1997; Vandesompele et al, 1998; Clark et al, 2002;
Willis et al, 2003). We recently performed an extensive survey on
the distribution and frequency of the 17q23 copy number increases
in 3520 tumours representing 166 different tumour types
(Andersen et al, 2002). The results confirmed previous data and
indicated that increased 17q23 copy number occurs most
commonly in brain, lung, breast, ovarian, urinary bladder, and
soft tissue tumours, although high-level amplification was
observed exclusively in breast cancer. Importantly, the increased
copy number of 17q23 region has also been associated with
tumour progression (Andersen et al, 2002) and with poor
prognosis in breast cancer (Isola et al, 1995; Barlund et al,
2000a), ovarian clear cell adenocarcinoma (Hirasawa et al, 2003),
neuroblastoma (Saito-Ohara et al, 2003), and acute myelogenous
leukaemia (Morerio et al, 2001). Taken together, these data suggest
that the genes affected by the 17q23 amplification contribute to
cancer pathogenesis.
In breast cancer, several studies have been performed to define
the limits of the 17q23 amplicon (Barlund et al, 1997, 2000b; Couch
et al, 1999; Erson et al, 2001; Monni et al, 2001; Wu et al, 2001).
Based on the combination of data from these studies and the
current information available in the human genome databases
(http://www.ncbi.nlm.nih.gov/mapview/ and http://www.ensembl.
org/Homo_sapiens/index.html), the amplicon is considerably large
covering an approximately 5Mb region at 17q23. A number of
studies have also aimed to uncover the possible target genes for
this amplification, mainly by looking at correlation between
amplification and high-level mRNA expression. One of the first
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sgenes to be identified as a potential oncogene in this region was the
ribosomal protein S6 kinase, RPS6KB1 (Couch et al, 1999; Barlund
et al, 2000a). Thereafter several other putative target genes have
been proposed including APPBP2 (also known as PAT1), RAD51C,
TBX2, TRIM37 (MUL), THRAP1 (TRAP240), PPM1D, and BRIP1
(Barlund et al, 2000b; Wu et al, 2000, 2001; Erson et al, 2001;
Monni et al, 2001; Bulavin et al, 2002; Li et al, 2002). However,
these studies were carried out at a time when the genome sequence
of this region was incomplete and thus all genes within this region
had not been identified. In addition, these previous studies mainly
concentrated on the analysis of established breast cancer cell lines
and the expression levels of only five genes from this region have
been evaluated in a small number of primary breast tumours
(Couch et al, 1999; Barlund et al, 2000b; Li et al, 2002).
In the present study, we aimed to further characterise the
molecular consequences of the 17q23 amplification on gene
expression levels in primary breast tumours. To this end, all
known genes localised within the 5Mb amplicon at 17q23 were
obtained from publicly available databases and their expression
levels were measured in 26 primary breast tumours using
quantitative real-time reverse transcriptase-polymerase chain
reaction (qRT-PCR). Our data revealed that high-level amplifica-
tion at 17q23 in primary breast cancer leads to coordinated
overexpression of 11 adjacent genes located at a 1.56Mb central
region of the amplicon.
MATERIALS AND METHODS
Primary tumours and breast cancer cell lines
Freshly frozen primary breast tumour specimens and correspond-
ing paraffin-embedded tissue samples from 26 breast cancer
patients were acquired from the Department of Pathology,
Tampere University Hospital. These samples represent a subset
of a larger material that has been described in detail previously
(Rauta et al, 2006). The clinicopathological characteristics of these
26 tumour samples are presented in Table 1. The mean age of the
patients at diagnosis was 62 years (range 38–84). The patients had
not received any therapy before tumour removal. The use of these
specimens in this study was approved by the Ethics Committee of
the Pirkanmaa Hospital District and by the National Authority for
Medicolegal Affairs in Finland.
Two breast cancer cell lines BT-474 and MCF7 were included in
this study. Pancreatic cancer cell lines PANC-1 and HUPT3 as well
as prostate cancer cell lines DU145 and PC-3 were used as controls
in RT-PCR analyses. HUPT3 cell line came from the German
Collection of Micro-organisms and Cell Cultures (Braunschweig,
Germany), all other cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). Cell lines
were cultured under recommended conditions. Normal testis and
pancreas cDNA (Ambion, Foster City, CA, USA) were also used as
controls in RT-PCR analyses. Human Mammary Gland (HMG)
cDNA was from BD Biosciences Clontech (Palo Alto, CA, USA).
Copy number analysis by fluorescence in situ
hybridisation
Three pairs of bacterial artificial chromosome (BAC) clones
corresponding to the 17q23 chromosome region (probe set A:
RP11-579A4 and RP11-579O24; probe set B: RP11-634F5 and
RP11-1081E4; probe set C: RP11-269G24 and CTD-2501B8) were
identified from public databases (http://www.ncbi.nlm.nih.gov/
mapview/ and http://www.ensembl.org). BAC DNA was labelled
with SpectrumOrange-dUTP (Vysis, Downers Grove, IL, USA) by
random priming and a SpectrumGreen labelled chromosome 17
probe (Vysis) was used as a reference. Fluorescence in situ
hybridisation (FISH) to normal metaphase chromosomes was
performed to confirm that the clone contigs recognised a single
copy target at 17q23. Fluorescence in situ hybridisation on
paraffin-embedded breast tumour samples was performed using
a modified Paraffin Pretreatment Reagent kit protocol (Vysis) as
described previously (Rauta et al, 2006). Hybridisation signals
were analysed using an Olympus BX50 epifluorescence microscope
(Tokyo, Japan) using an  60 objective (NA 1.4). Specimens
containing a three to fivefold increase in the number of gene
specific probe signals, as compared with the chromosome 17
centromere signals, were considered to be moderately amplified. In
addition, specimens containing a fivefold or higher increase in the
number of PPM1D signals or tight clusters of signals were
considered to be highly amplified. The results using the RP11-
634F5 and RP11-1081E4 BAC contigs were included in a previous
publication (Rauta et al, 2006).
RNA isolation and cDNA synthesis
Total RNA was extracted from cancer cell lines using TRIZOL
Reagent (Invitrogen, Carlsbad, CA, USA) according to manufac-
turer’s instructions. For primary tumour samples, a representative
tumour area was selected from freshly frozen tumour specimen
based on haematoxylin–eosin stained tissue section and a core-
biopsy (+2mm) was obtained for RNA isolation. Tumour tissues
were homogenised with a syringe and a needle (20G, +0.9mm)
and total RNA was extracted with RNeasy Mini Kit (Qiagen,
Valencia, CA, USA). First-strand cDNA synthesis for both cell line
and primary tumour RNAs was performed using SuperScript II
reverse transcriptase and random hexamer primers (Invitrogen).
Table 1 Clinicopathological characteristics of 26 primary breast tumours
Variable n %
Tumour type
Infiltrating ductal 22 84.6
Infiltrating lobular 4 15.4
Tumour size
o20mm 12 46.2
X20mm 14 53.8
Histological grade
a
I 0 0.0
II 8 36.4
III 14 63.6
Stage
T1 11 42.3
T2 5 19.2
T3 4 15.4
T4 6 23.1
Nodal status
Negative 12 46.2
Positive 11 42.3
Not available 3 11.5
ER
Positive 21 81.8
Negative 5 19.2
PR
Positive 13 50.0
Negative 13 50.0
ERBB2
Negative 21 80.8
Positive 5 19.2
aHistological grade was determined only from the infiltrating ductal carcinomas.
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Gene specific primers for 29 genes from the 17q23 region (primer
sequences are available on request) were obtained from TIB
MolBiol (Berlin, Germany). The PCR contained 1 PCR Gold
buffer (Applied Biosystems, Foster city, CA, USA), 1.5mM MgCl2,
0.2mM dNTPs each, 0.2–0.4mM gene specific primers, 1.5–2.5
units of Amplitaq Gold DNA polymerase (Applied Biosystems),
and 1ml cDNA template (MCF7 or BT474) adjusted to 50ml with
sterile H2O. The PCR programme began with initial denaturation
at 951C for 5min, followed by 35 cycles of denaturation at 951C for
30s, annealing at 551C for 60s and elongation at 721C for 60s, with
final elongation at 721C for 10min. The PCR products were run on
a 1.5% agarose gel. For those genes with no detectable expression
in MCF7 and BT-474 cells, the functionality of the PCR primers
was verified using cDNA from PANC-1, HUPT3, DU145, PC-3,
normal testis or normal pancreas as a template.
Quantitative real-time RT-PCR
DNA Hybridisation Probe Sets for 24 genes at 17q23 and the
housekeeping gene TATA-box-binding protein (TBP) were
obtained from TIB MolBiol (Berlin, Germany). The PCR reactions
were performed in the LightCycler apparatus using the LC
FastStart DNA Hybridisation Probes Kit according to manufac-
turer’s instructions (Roche Diagnostics, Mannheim, Germany).
Briefly, the PCR contained 1 LightCycler FastStart DNA Master
HybProbe mix (Roche Applied Science, Mannheim, Germany),
4mM MgCl2, 0.2–0.4mM gene specific probes, 0.8mM gene specific
primers, and 1.5ml cDNA template adjusted to 20ml with sterile
H2O. After 10min of initial denaturation at 951C, the cycling
conditions (55 cycles) were as follows: denaturation at 951C for
10s, annealing at 55–581C for 10–20s, and elongation at 721C for
6–12s depending on the gene of interest. Quantitative analysis was
performed using the LightCycler software according to the fit-
point method as described earlier (Kauraniemi et al, 2003). The
expression levels were normalised against the housekeeping gene
TBP.
Statistical analysis
For each gene, two-tailed Mann–Whitney U-test was used to
examine the possible statistical significance of differences in
expression levels between the three tumour groups. Three separate
comparisons (high vs moderate, high vs no, and moderate vs no
amplification tumour group) were made.
RESULTS
Primary tumour selection and copy number analysis
We had previously determined the DNA copy number levels within
the centre of the 17q23 amplicon (at the PPM1D gene locus) in a
set of 146 primary breast tumours by using formalin-fixed,
paraffin-embedded samples (Rauta et al, 2006). On the basis of
these data, a total of 26 tumours, including eight cases with
increased copy number and 18 tumours with no copy number
increase, were selected for this study owing to the availability of
freshly frozen tumour material required for the mRNA expression
analyses. To determine further the 17q23 amplification status in
this set of samples, we used additional probe pairs from both ends
of the 5Mb amplicon and determined their copy number levels by
FISH (Table 2). As might be expected, the 18 non-amplified
tumours did not show copy number increase with the additional
probe sets either (data not shown). The eight amplified cases
demonstrated more or less consistent copy number changes across
the entire amplicon and could now be classified into groups with
high (n¼4) and moderate (n¼4) level of amplification (Table 2).
Transcript identification
On the basis of previous studies (Barlund et al, 1997, 2000b; Couch
et al, 1999; Erson et al, 2001; Monni et al, 2001; Wu et al, 2001) and
the current genome sequence information (http://www.ncbi.nlm.-
nih.gov/mapview/ and http://www.ensembl.org/Homo_sapiens/in-
dex.html), the 17q23 amplicon is restricted to an B5Mb region
(53.95–59.02Mb) and contains 29 genes with known function
(Figure 1, Table 3). First, the expression levels of these 29 genes
were screened by regular RT-PCR in MCF7 and BT-474 breast
cancer cell lines that are known to harbour high level 17q23
amplification (Couch et al, 1999; Barlund et al, 2000a; Monni et al,
2001). Five (SEPT4, TEX14, CA4, MRC2, and KCNH6) of the 29
genes had either very low or undetectable expression in both MCF7
and BT-474 cells (data not shown) and were thus excluded from
further analyses based on the fact that a potential amplification
target gene is expected to show elevated mRNA expression.
Expression screen in primary breast tumours
The expression levels of the remaining 24 genes from the 17q23
amplicon were then measured in the 26 primary breast tumours
using qRT-PCR. Two genes, PTRH2 and ACE, showed considerably
higher expression levels than any other gene within this region
Table 2 Copy number levels at the 17q23 amplicon relative to
chromosome 17 centromere in eight primary breast tumours by FISH
Probe sets
a
Tumour number A
b B
c C
d
High
133 1.5 Amp
e 3
206 Amp
e Amp
e 2.5
209 Amp
e Amp
e Amp
e
236 1 451
Moderate
249 1.5 3.5 1
251 3 3.5 3.5
255 2 3 2
256 3.5 3.5 3
FISH¼fluorescence in situ hybridisation.
aSee Materials and Methods.
bIncludes
RAD51C-PPM1E genes.
cIncludes PPM1D gene.
dIncludes CYB561-ACE-KCNH6-
WDR68 genes.
eTight cluster of signals indicative of amplification.
SEPT4
DHX40
53.5 54.5 55.5 56.5 57.5 58.5 59.0 Mb
TEX14
RAD51C
PPM1E
TRIM37
YPEL2 PTRH2
TUBD1
  RPS6KB1
ABC1
CA4
USP32
APPBP2
PPM1D
BCAS3
TBX2
TBX4
BRIP1
THRAP1
TLK2
MRC2
ACE
KCNH6
WDR68 CYB561 TMEM49
FAM33A CLTC
Figure 1 Physical map of the 17q23 amplicon. The known genes mapping to the B5Mb minimal region of amplification at 17q23 are represented using
horizontal lines and their orientation is indicated with arrowheads.
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normal HMG, and therefore does not appear to be interesting as
putative target gene for 17q23 amplification. The expression levels
of PPM1E were very low across all 26 tumour samples and,
additionally, both PPM1E and TBX4 showed highest expression
levels in non-amplified tumour samples (Table 3, Figure 2).
Finally, the expression levels of the 24 genes within the 17q23
amplicon were compared between the three tumour groups. A
statistically significant (Po0.01) difference between the high level
and no amplification groups were observed for a set of 11 genes
(FAM33A, DHX40, CLTC, PTRH2, TMEM49, TUBD1, RPS6KB1,
ABC1, USP32, APPBP2, and PPM1D) (Figure 3). All of these, except
FAM33A and USP32, also showed significant difference (Po0.05)
in expression levels between the high-and moderate-level ampli-
fication groups suggesting that these genes are activated by high-
level copy number increases (Figure 3). No difference between the
moderate and the no amplification tumour groups were observed.
Interestingly, these 11 genes are located adjacent to each other
within a 1.56Mb region (54.54–56.10Mb) at the centre of the
17q23 amplicon (Figures 1 and 2). It was even more intriguing that
only a single gene, YPEL2, within this region did not demonstrate
an association between amplification and increased mRNA
expression.
DISCUSSION
Several studies have illustrated recurrent amplification of 17q23 in
various human tumours and its association to poor clinical
outcome (Isola et al, 1995; Barlund et al, 2000a; Morerio et al,
2001; Andersen et al, 2002; Hirasawa et al, 2003; Saito-Ohara et al,
2003). These studies have proposed multiple genes from this
region to be important for cancer development and progression
and thus promising targets for diagnostic, prognostic, and
therapeutic approaches. However, no systematic survey of all
genes within the 17q23 region has earlier been performed in
primary tumour material. Here 29 known genes located within the
Table 3 List of the 29 known genes located in the 5Mb minimal region of amplification at 17q23 and their minimum, maximum and median expression
levels in 26 primary breast tumours
Gene Description Min Max Median
SEPT4 Peanut-like protein 2 ND ND ND
TEX14 Testis expressed sequence 14 ND ND ND
RAD51C DNA repair protein RAD51 homolog 0.0 1.9 0.3
PPM1E Protein phosphatase 1E 0.0 1.7 0.0
TRIM37 Tripartite motif-containing 37 protein 0.0 1.1 0.2
FAM33A Family with sequence similarity 33, member A 0.0 3.3 0.3
YPEL2 Yippee-like 2 protein 0.1 1.0 0.3
DHX40 DEAH (Asp-Glu-Ala-His) box polypeptide 40 0.0 4.5 0.2
CLTC Clathrin heavy chain 1 0.0 3.7 0.4
PTRH2 Peptidyl-tRNA hydrolase 2 0.1 14.8 1.4
TMEM49 Transmembrane protein 49 0.0 1.2 0.2
TUBD1 Tubulin d chain 0.0 2.4 0.3
RPS6KB1 Ribosomal protein S6 kinase 0.0 1.0 0.2
ABC1 Amplified in breast cancer 0.0 1.7 0.3
CA4 Carbonic anhydrase IV precursor ND ND ND
USP32 Ubiquitin C-terminal hydrolase 32 0.0 1.5 0.3
APPBP2 Amyloid b precursor protein binding protein 2 0.0 1.6 0.1
PPM1D Protein phosphatase 2C d isoform, magnesium-dependent 0.0 2.8 0.2
BCAS3 Breast carcinoma amplified sequence 3 0.1 2.7 0.3
TBX2 T-box transcription factor TBX2 0.0 0.7 0.1
TBX4 T-box transcription factor TBX4 0.0 9.0 0.3
BRIP1 BRCA1 interacting protein C-terminal helicase 1 0.0 2.1 0.2
THRAP1 Thyroid hormone receptor-associated protein 0.0 1.1 0.2
TLK2 Serine/threonine-protein kinase tousled-like 2 0.1 1.6 0.3
MRC2 Mannose receptor, C type 2 ND ND ND
CYB561 Cytochrome b561 0.3 9.2 1.3
ACE Angiotensin-converting enzyme, somatic isoform precursor 4.0 233.0 32.1
KCNH6 Potassium voltage-gated channel, subfamily H, member 6 ND ND ND
WRD68 WD-repeat protein 68 0.1 1.8 0.8
ND¼not determined (low or now expression in breast cancer cell lines MCF7 and BT-474 with high-level amplification).
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Figure 2 Schematic representation of expression levels of 24 known
genes within the 17q23 chromosomal region in 26 primary breast tumours
and normal HMG. Primary tumours are arranged according to their 17q23
amplification status and genes are organised based on their physical order
at the 17q23 region from centromere to telomere. Expression levels were
determined using qRT-PCR and were normalised against a housekeeping
gene TBP. The relative expression values of each gene were median-
corrected and displayed using a colour code (shown at the bottom).
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scommon amplified segment at 17q23 were defined. Five of these
were excluded from further analysis, because they showed very low
or undetectable expression in cell lines with high level amplifica-
tion. The expression levels of the remaining 24 genes were then
examined using qRT-PCR in 26 primary breast tumours to assess
their role as putative target genes for 17q23 amplification in breast
cancer.
Our systematic study revealed eleven genes (FAM33A, DHX40,
CLTC, PTRH2, TMEM49, TUBD1, RPS6KB1, ABC1, USP32,
APPBP2, PPM1D) that showed significantly (Po0.01) higher
expression levels in primary breast tumours with high level
17q23 amplification compared to tumours without amplification.
Interestingly, these eleven genes are all located within a 1.56Mb
region at the centre of the 17q23 amplicon. The amplicon core also
includes one additional gene, YPEL2, but for unknown reasons it
does not demonstrate copy number dependent overexpression. As
only very little is known about the function of this gene, it is not
possible to speculate on the basis of this phenomenon. Overall, our
findings are in good agreement with previous studies that have
implicated gene copy number alterations as significant determi-
nants of gene expression patterns (Hyman et al, 2002; Pollack et al,
2002; Wolf et al, 2004; Fridlyand et al, 2006). However, it has to be
noted that the tumour group with moderate amplification showed
expression levels similar to those seen in the non-amplified
tumours, indicating that low level copy number increases at this
region did not have a significant effect on gene expression levels.
This finding is supported by recent studies demonstrating that the
high-level amplifications but not copy number gains are associated
with poor prognosis in various tumour types (Sticht et al, 2005;
Staebler et al, 2006). In summary, the qRT-PCR screen demon-
strated that high level amplification at 17q23 in breast cancer leads
to concomitant overexpression of virtually all genes within the
amplicon core.
Several genes have earlier been proposed as putative target genes
of the 17q23 amplification. These include RPS6KB1, APPBP2, and
PPM1D (Couch et al, 1999; Barlund et al, 2000a,b; Wu et al, 2001;
Bulavin et al, 2002; Li et al, 2002) that also showed strong
association between amplification and increased expression in our
0
1
2
3
4
0
1
2
3
4
5
0
1
2
3
4
0
4
8
0
1
2
3
0
1
2
3
4
FAM33A P=0.0044 P=0.0025 P=0.0025 CLTC DHX40
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
High Moderate No High Moderate No High Moderate No
PTRH2
P=0.0033
TMEM49
APPBP2
RPS6KB1 ABC1 USP32
16
12
1.5
1.0
0.5
0.0
High Moderate No High Moderate No High Moderate No
High Moderate No High Moderate No High Moderate No
High Moderate No High Moderate No
P=0.0074
2.0
1.5
1.0
0.5
0.0
P=0.0044
TUBD1
P=0.0033
2.0
1.5
1.0
0.5
0.0
2.0
1.5
1.0
0.5
0.0
2.0
1.5
1.0
0.5
0.0
P=0.0025 P=0.0033
P=0.0025 PPM1D P=0.0025
Figure 3 Comparison of FAM33A, DHX40, CLTC, PTRH2, TMEM49, TUBD1, RPS6KB1, ABC1, USP32, APPBP2, and PPM1D expression in highly,
moderately, and no amplification tumour groups by qRT-PCR. Median value of expression is indicated by a horizontal line. Two-tailed Mann–Whitney U-test
was used to assess the statistical significance of differences in expression levels between tumour groups. P-values between highly non-amplified groups are
shown.
A systematic survey of the 17q23 amplicon in breast cancer
JP a ¨rssinen et al
1262
British Journal of Cancer (2007) 96(8), 1258–1264 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sprimary tumour material. Earlier studies have also implicated
RAD51C, TRIM37, TBX2, THRAP1, and BRIP1 as genes whose
expression correlates with amplification (Barlund et al, 2000b; Wu
et al, 2000, 2001; Erson et al, 2001; Monni et al, 2001). In our
tumour series, these genes did also show elevated expression in
some samples with high level amplification, but the difference in
expression levels between the high and no amplification tumour
groups, did not reach statistical significance. This finding might
reflect the fact that we focussed solely on the analysis of primary
tumour material instead of established breast cancer cell lines that
were mainly used in these previous studies. Finally, our data
revealed seven other protein coding genes (FAM33A, DHX40,
CLTC, PTRH2, TMEM49, TUBD1, ABC1, and USP32) that have not
been implicated previously in 17q23 studies, but whose expression
was clearly associated with copy number status in primary breast
tumours. Taken together, our results highlight a set of new genes
that are overexpressed because of the 17q23 amplification in breast
cancer and thus might contribute to the tumour phenotype.
Similar observations on overexpression of multiple genes within
an amplicon have been reported previously in several occasions.
For example, recent studies identified a 1Mb segment of common
amplification at 8p11–12 in breast cancer and demonstrated that it
contains at least 14 candidate genes showing a strong correlation
between amplification and overexpression (Garcia et al, 2005;
Gelsi-Boyer et al, 2005). At 11q13, which is amplified in a wide
variety of tumours (Saunders et al, 2000; Gollin, 2001, 2004),
Huang et al (2006) constructed a detailed 3.6Mb map of the
amplicon core and showed that most of the genes in that region are
overexpressed in amplified tumours and cell lines. Similarly, we
have demonstrated that amplification of a 280kb minimal
common region at 17q12 in breast cancer leads to simultaneous
increase of expression levels of all genes within that genomic
segment (Kauraniemi et al, 2001). In general, these data implicate
that despite the size of the affected region, the vast majority of the
genes within amplicons are overexpressed and hence amplification
events typically lead to overexpression of multiple genes. Owing to
this tight association between amplification and elevated gene
expression, it is difficult to determine which of the genes within
particular amplicon actually contribute to tumour pathogenesis. It
is likely that all of the overexpressed genes are not critical for
cancer progression but are overexpressed merely because of their
location within the amplicon. However, it is also possible that,
instead of a single target gene, amplicons are driven by a set of
genes whose simultaneous overexpression provides growth ad-
vantage to cancer cells (Huang et al, 2006; Kao and Pollack, 2006).
Traditionally, the search for amplification target genes has been
based on two primary schemes; namely location within the
maximal amplitude of the amplicon and overexpression of the
putative target gene. Our results demonstrate that a whole set of
genes, 11 of the 12 known genes within the 1.56Mb core region, is
overexpressed in primary breast tumours with high level
amplification at 17q23. Owing to such coordinated overexpression
of genes in the amplification core, overexpression alone is not
sufficient to highlight putative target genes but functional studies
are required to uncover the possible biological and clinical
significance of candidate genes.
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